The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

NPA chairman Nick Kaye told the PA news agency that while obesity is "one of the biggest challenges facing" the UK, they are ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

The National Pharmacy Association (NPA) has written to regulators calling for tougher rules to be introduced around sale of weight loss jabs online.

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

A major analysis of more than 1.2 million medical records has found popular diabetes and weight loss drugs, including Ozempic and Wegovy, may also reduce the risk of other health issues.

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

COPENHAGEN--Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep ...

In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond weight loss. Published in the journal Nature Medicine, this new study ...

The rules over who can access weight loss jabs puts patients safety at risk, warns the National Pharmacy Association amid a boom in demand ...